Uloric Related Published Studies
Well-designed clinical trials related to Uloric (Febuxostat)
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. [2011.07]
An allopurinol-controlled, multicenter, randomized, open-label, parallel
between-group, comparative study of febuxostat (TMX-67), a non-purine-selective
inhibitor of xanthine oxidase, in patients with hyperuricemia including those
with gout in Japan: phase 2 exploratory clinical study. [2011]
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel
between-group, comparative study of febuxostat (TMX-67), a non-purine-selective
inhibitor of xanthine oxidase, in patients with hyperuricemia including those
with gout in Japan: phase 3 clinical study. [2011]
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. [2010]
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. [2009.02]
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. [2008.11.15]
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. [2008.03]
Febuxostat. [2008]
Well-designed clinical trials possibly related to Uloric (Febuxostat)
Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. [2011.08]
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. [2010.12]
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. [2008.06]
Other research related to Uloric (Febuxostat)
An allopurinol-controlled, multicenter, randomized, double-blind, parallel
between-group, comparative study of febuxostat in Chinese patients with gout and
hyperuricemia. [2014]
Cost-effectiveness of febuxostat in chronic gout. [2014]
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery
patients (NU-FLASH Trial). [2013]
Febuxostat for treating chronic gout. [2012]
Women with gout: The efficacy and safety of urate-lowering with febuxostat and allopurinol. [2011.11.02]
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. [2011.09]
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. [2011.06]
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. [2011.06]
Febuxostat for treatment of chronic gout. [2011.03.01]
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. [2011.02]
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. [2011.02]
Renal function in gout: long-term treatment effects of febuxostat. [2011.01]
International position paper on febuxostat. [2010.08]
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. [2010.07]
Urate-lowering therapy for gout: focus on febuxostat. [2010.06]
International position paper on febuxostat. [2010.04.18]
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. [2010.04]
Management of hyperuricemia in gout: focus on febuxostat. [2010.02.02]
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of
febuxostat, a non-purine selective inhibitor of xanthine oxidase. [2010]
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. [2009.11]
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. [2009.10]
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. [2009.06]
Febuxostat: a new treatment for hyperuricaemia in gout. [2009.05]
Febuxostat: a new agent for lowering serum urate. [2009.04]
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. [2008.11]
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. [2008.09]
In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. [2008.05]
[New antihyperuricemic medicine: febuxostat, Puricase, etc] [2008.04]
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. [2008.04]
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. [2008]
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. [2007]
Other possibly related research studies
Gout--what are the treatment options? [2009.06]
Update on emerging urate-lowering therapies. [2009.03]
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. [2009.04]
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? [2008]
[Inhibitors of xanthine oxidoreductase] [2008.04]
Refractory gout: what is it and what to do about it? [2008.03]
Gateways to clinical trials. [2007.12]
Hyperuricemia and gout: new insights into pathogenesis and treatment. [2007]
Assessment of outcome in clinical trials of gout--a review of current measures. [2007.12]
[Crystal-induced arthritis--old but important] [2007.07]
Uricase and other novel agents for the management of patients with treatment-failure gout. [2007.06]
Emerging therapies in the long-term management of hyperuricaemia and gout. [2007.04]
Therapeutic advances in gout. [2007.03]
[The clinical picture of gout is changing] [2010]
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction. [2010.06]
Progress in the pharmacotherapy of gout. [2010.03]
Update on gout: new therapeutic strategies and options. [2010.01]
The role of urate and xanthine oxidase in vascular oxidative stress: future directions. [2009]
[Crystal-induced activation of the inflammasome: gout and pseudogout] [2009.11]
[Gout - regardless of therapeutic options a "forgotten" disease]. [2011.08]
[Calcium pyrophosphate deposition disease]. [2011.09]
Managing your patient with gout: a review of treatment options. [2011.05]
Managing gout: how is it different in patients with chronic kidney disease? [2010.12]
The current state of care in gout: Addressing the need for better understanding of an ancient disease. [2010.11]
Crystal arthropathies: recognizing and treating "the gouch". [2010.12]
Advances in gout: some answers, more questions. [2010]
Gout therapeutics: new drugs for an old disease. [2011.01.08]
Update on gout and hyperuricemia. [2010.02]
Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. [2014]
Interventions for tophi in gout. [2014]
Allopurinol for chronic gout. [2014]
|